FINWIRES · TerminalLIVE
FINWIRES

Update: WTI Oil Settles Below US$100 As U.S. And Iran Fail To Reach A Deal; U.S. Promises To Blockade Iran

-- West Texas Intermediate (WTI) crude oil tested the US$100 per barrel mark on Monday before falling back after the United States said it will blockade Iran's ports after weekend peace talks in Pakistan ended without an agreement to end hostilities.

WTI crude oil for May delivery closed up US$2.51 to settle at US$99.08 per barrel, after earlier touching US$105.63, while June Brent oil was last seen up US$3.92 to US$99.12.

Direct and indirect talks between Iran and the United States failed to reach an agreement, with Iran refusing to agree to U.S. demands that it end its uranium-enrichment program. In response to the unsuccessful negotiations, the United States said it will blockade Iran's ports and block any ships paying Iran for passage through the Strait of Hormuz. Iran responded by threatening attacks on ports in the Persian Gulf and Sea of Oman, according to the Wall Street Journal.

Failure to reach a deal leaves the Strait of Hormuz closed to tanker traffic, continuing to block 20% of daily oil demand supplied by Persian Gulf nations. The largest-ever supply shock likely to be magnified by the oncoming high-demand summer season.

"Once again, high stakes negotiations between the US and Iran deadlocked over Washington's zero uranium enrichment demand, setting the stage for further escalation in the 6-week war and prolonged supply disruptions in advance of summer driving season," Helima Croft, Head of Global Commodity Strategy and MENA Research at RBC Capital Markets, wrote.

"In the absence of a negotiated deal, the White House is essentially left with the option of a strategic retreat that would leave Iran with de facto control over the Strait or a military escalation aimed at

eliminating the Tehran tollbooth."

相關文章

Asia

企業差旅管理公司預計將衝回至多1.18億英鎊的收入,與先前的業績相比將出現下滑。

根據週三提交給澳洲證券交易所的文件,Corporate Travel Management(ASX:CTD)預計將從2025財年及之前年度的業績中衝回至多1.18億英鎊的收入,高於此前預估的7760萬英鎊。 此前,該公司聘請畢馬威會計師事務所(KPMG)對部分年度的業績進行法務會計審查。畢馬威在審查中發現,該公司在英國已完成的客戶合約和其他收入的確認方面存在一些問題。 該公司表示,根據與部分客戶的商業談判結果,可能需要在上半年業績中衝回至多約1,000萬英鎊的收入。審查證實,部分客戶被收取了高於合約約定的費用。 Corporate Travel Management表示,已對其英國業務進行了“重大調整”,尤其是在財務控制和營運流程方面。該公司還補充說,審查並未在其他地區發現任何問題。 該公司計劃在今年第二季發布經審計的 2025 財年財務報表和經審核的 2026 財年上半年財務報表。

$ASX:CTD
Asia

北方星資源公司3月季度黃金銷售額下降

根據週三提交給澳洲證券交易所的文件,北方星資源公司(ASX:NST)表示,截至2025年3月季度,該公司黃金總銷量為380,807盎司,綜合維持成本(AISC)為每盎司2,709澳元。 先前提交的文件顯示,截至2025年3月季度,該公司黃金總銷量為385,441盎司,綜合維持成本為每盎司2,246澳元。 該公司預計2026財年黃金銷售量將超過150萬盎司,綜合維持成本預計在每盎司2,600澳元至2,800澳元之間。 該公司在支付3.47億澳元現金股利後,淨現金為3.2億澳元,截至3月31日,其現金及貴金屬總持有量為11.8億澳元。 北方之星資源公司(Northern Star Resources)的股價在最近的周三交易中下跌了約2%。

$ASX:NST
Asia

衛材與默克共同進行的腎癌藥物第三期臨床試驗未能達到存活終點

日本製藥公司衛材(Eisai,TYO:4523)和美國默克公司(Merck)的實驗性聯合療法在一項3期臨床試驗中未能達到無惡化存活期和總存活期這兩個主要終點。 根據週二發布的聯合聲明,該試驗旨在評估晚期透明細胞腎細胞癌(一種約佔所有腎癌病例80%的腎癌)的一線治療方案。 LITESPARK-012研究在1688名患者中測試了兩種方案:Keytruda合併Lenvima和Welireg,以及MK-1308A(Keytruda與一種在研抗體的複方製劑)合併Lenvima,並與已確立的Keytruda合併Lenvima方案進行比較。 中期分析顯示,與標準治療相比,兩種實驗性聯合方案均未能達到研究的兩個主要目標,即改善總存活期和無惡化存活期。

$TYO:4523